ArticleFrontiers in oncology2025
Breast cancer burden in the United States (1990-2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years. Methods: Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed four measures: prevalence, incidence, death, and disability-adjusted life years (DALYs), stratified by sex, age, U.S. states, and socio-demographic index (SDI). Results: BC burden in the U.S. has decreased, with reductions in age-standardized rates of prevalence, incidence, mortality, and DALYs for both sexes. The overall age-standardized prevalence rate dropped from 695.0 (653.5-741.5)/100,000 in 1990 to 556.0 (525.2-584.7)/100,000 in 2021. The ASIR declined from 68.3 (65.1-70.3)/100,000 to 51.7 (48.4-54.1)/100,000. Death rates fell from 15.9 (14.9-16.5)/100,000 to 9.4 (8.5-9.9)/100,000, while DALYs decreased from 485.1 (462.9-507.0)/100,000 to 277.4 (260.1-294.8)/100,000 over the same period. Burden varies by state and SDI: in 2021, low-SDI states, Kentucky and Louisiana had the highest prevalence and incidence, while Louisiana and Mississippi had the highest mortality. Projections suggest a continued downward trend through 2036. Conclusions: BC burden in the U.S. decreased overall, but disparities persist across sex, age groups, and states with varying SDI levels. Addressing risk factors and improving healthcare access are essential to further reduce BC burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.